ABCC1 p.Tyr1189Ser
Predicted by SNAP2: | A: D (63%), C: N (57%), D: D (85%), E: D (80%), F: N (66%), G: D (75%), H: D (63%), I: D (59%), K: D (75%), L: D (63%), M: D (63%), N: D (71%), P: D (85%), Q: D (66%), R: D (71%), S: D (63%), T: D (66%), V: D (53%), W: D (71%), |
Predicted by PROVEAN: | A: D, C: D, D: D, E: D, F: D, G: D, H: D, I: D, K: D, L: D, M: D, N: D, P: D, Q: D, R: D, S: D, T: D, V: D, W: D, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] Role of two adjacent cytoplasmic tyrosine residues... Biochem Pharmacol. 2005 Feb 1;69(3):451-61. Epub 2004 Dec 16. Conseil G, Deeley RG, Cole SP
Role of two adjacent cytoplasmic tyrosine residues in MRP1 (ABCC1) transport activity and sensitivity to sulfonylureas.
Biochem Pharmacol. 2005 Feb 1;69(3):451-61. Epub 2004 Dec 16., [PMID:15652236]
Abstract [show]
The human ATP-binding cassette (ABC) protein MRP1 causes resistance to many anticancer drugs and is also a primary active transporter of conjugated metabolites and endogenous organic anions, including leukotriene C(4) (LTC(4)) and glutathione (GSH). The sulfonylurea receptors SUR1 and SUR2 are related ABC proteins with the same domain structure as MRP1, but serve as regulators of the K(+) channel Kir6.2. Despite their functional differences, the activity of both SUR1/2 and MRP1 can be blocked by glibenclamide, a sulfonylurea used to treat diabetes. Residues in the cytoplasmic loop connecting transmembrane helices 15 and 16 of the SUR proteins have been implicated as molecular determinants of their sensitivity to glibenclamide and other sulfonylureas. We have now investigated the effect of mutating Tyr(1189) and Tyr(1190) in the comparable region of MRP1 on its transport activity and sulfonylurea sensitivity. Ala and Ser substitutions of Tyr(1189) and Tyr(1190) caused a > or =50% decrease in the ability of MRP1 to transport different organic anions, and a decrease in LTC(4) photolabeling. Kinetic analyses showed the decrease in GSH transport was attributable primarily to a 10-fold increase in K(m). In contrast, mutations of these Tyr residues had no major effect on the catalytic activity of MRP1. Furthermore, the mutant proteins showed no substantial differences in their sensitivity to glibenclamide and tolbutamide. We conclude that MRP1 Tyr(1189) and Tyr(1190), unlike the corresponding residues in SUR1, are not involved in its differential sensitivity to sulfonylureas, but nevertheless, may be involved in the transport activity of MRP1, especially with respect to GSH.
Comments [show]
None has been submitted yet.
No. Sentence Comment
59 Tyr substitutions were generated in the pGEM-3Z plasmids according to the manufacturer`s instructions with the following mutagenic primers (substituted nucleotides are in bold) obtained from Integrated DNA Technologies: Y1189A (50 -GAT GCT GGG GAT CGC GGC CTT CTG GTT CTC-30 ), Y1189S (50 -GAT GCT GGG GTA ACT GGC CTT CTG G-30 ), Y1190A (50 -C CAC GAT GCT CGG GGC ATA GGC CTT C-30 ), Y1190S (50 -C GAT GCT GGG ACT ATA GGC CTT C30 ).
X
ABCC1 p.Tyr1189Ser 15652236:59:278
status: NEW111 Kinetic analysis of [3 H]GSH transport Km and Vmax values of ATP-dependent GSH transport by membrane vesicles (20 mg protein) were determined by measuring uptake at eight different [3 H]GSH concentrations (10-2500 mM for wild-type MRP1 and 5010,000 mM for Y1189S mutant MRP1) for 20 min at 37 8C in 60 ml of transport buffer containing components as described above [16].
X
ABCC1 p.Tyr1189Ser 15652236:111:256
status: NEW119 As shown in Fig. 3B, the ability of the mutants to support LTC4 uptake after 3 min was reduced by approximately 55 and 25% for Y1189A and Y1189S, respectively, and by approximately 40 and 50% for Y1190A and Y1190S, compared to wild-type MRP1.
X
ABCC1 p.Tyr1189Ser 15652236:119:138
status: NEW121 E217bG uptake by the Y1189A and Y1189S mutants was reduced by 30%, and by 55-65% for the Y1190A and Y1190S mutants.
X
ABCC1 p.Tyr1189Ser 15652236:121:32
status: NEW122 E13SO4 uptake was reduced by 35% in the case of Y1189S and by 60-65% for the Y1189A, Y1190A and Y1190S mutants.
X
ABCC1 p.Tyr1189Ser 15652236:122:48
status: NEW129 As shown in Fig. 4B, Y1189A, Y1189S, Y1190A and Y1190S exhibited a moderate (10-30%) decrease in azido-ATP labeling at 4 8C.
X
ABCC1 p.Tyr1189Ser 15652236:129:29
status: NEW130 When the amount of azido-ADP trapped by vanadate under hydrolysis conditions at 37 8C was measured, the Ala-substituted mutants Y1189A and Y1190A exhibited a reduction of 30-40% compared to wild-type MRP1, whereas little or no ( 10%) decrease in trapping was observed for the Ser-substituted Y1189S and Y1190S mutants (Fig. 4C).
X
ABCC1 p.Tyr1189Ser 15652236:130:292
status: NEW133 (A) Immunodot blot of membrane vesicles (0.5 and 1 mg protein) prepared from HEK293T cells transfected with wild-type (WT-MRP1) and mutant (Y1189A, Y1189S, Y1190A, Y1190S) MRP1 cDNAs.
X
ABCC1 p.Tyr1189Ser 15652236:133:148
status: NEW138 ; Y1189S, ~; Y1190A, *; Y1190S, *) cDNAs.
X
ABCC1 p.Tyr1189Ser 15652236:138:2
status: NEW143 Table 1 Summary of transport activities for Tyr1189 and Tyr1190 mutants of MRP1 Mutant %Wild-type MRP1 uptake activitya LTC4 b E217bG E13SO4 MTX GSH Y1189A 45 70 40 35 10 Y1189S 75 70 65 35 30 Y1190A 60 45 40 35 20 Y1190S 50 35 35 25 25 a The values shown are means of triplicate determinations in a single experiment and are representative of results obtained in two to three independent experiments. Values have been corrected for different MRP1 expression levels according to the immunoblot shown Fig. 3A.
X
ABCC1 p.Tyr1189Ser 15652236:143:171
status: NEW151 Kinetic analysis of [3 H]GSH transport To better understand the basis for the markedly reduced levels of GSH uptake by the Tyr mutants, the kinetic parameters of apigenin-stimulated GSH uptake by the Y1189S mutant were determined and compared to those of wild-type MRP1 (Fig. 6).
X
ABCC1 p.Tyr1189Ser 15652236:151:200
status: NEW154 (A) Immunoblot of membrane vesicles (1 mg protein) prepared from HEK293T cells transfected with wild-type (WT-MRP1a, b, c), and mutant (Y1189A, Y1189S, Y1190A, Y1190S) MRP1 cDNAs as in Fig 3A. (B) Membrane vesicles (20 mg protein) were incubated with 5 mM [a-32 P]-8N3-ATP at 4 8C for 5 min in transport buffer containing 5 mM MgCl2. Samples were photo-crosslinked, resolved by SDS-PAGE and exposed to film.
X
ABCC1 p.Tyr1189Ser 15652236:154:144
status: NEW164 Ala/Ser MRP1 mutants (Y1189A, Y1189S, Y1190A, Y1190S).
X
ABCC1 p.Tyr1189Ser 15652236:164:30
status: NEW169 that the Km (GSH) of Y1189S was increased 10-fold compared to that of wild-type MRP1 (1904 Æ 420 mM versus 162 Æ 29 mM).
X
ABCC1 p.Tyr1189Ser 15652236:169:21
status: NEWX
ABCC1 p.Tyr1189Ser 15652236:169:167
status: NEW170 In addition, the Vmax of GSH transport was also moderately increased (8.9 Æ 0.4 versus 12.4 Æ 1.0 nmol mgÀ1 protein after 20 min, respectively, for wild-type MRP1 and Y1189S).
X
ABCC1 p.Tyr1189Ser 15652236:170:182
status: NEW172 Ser mutation (Vmax/Km  103 = 54.9 versus 6.5 for wild-type MRP1 and the Y1189S mutant, respectively).
X
ABCC1 p.Tyr1189Ser 15652236:172:41
status: NEWX
ABCC1 p.Tyr1189Ser 15652236:172:78
status: NEW173 These results indicate that the mutation Y1189S altered mainly the uptake affinity of MRP1 for GSH and to a lesser extent the transport capacity of MRP1 for this tripeptide.
X
ABCC1 p.Tyr1189Ser 15652236:173:41
status: NEW177 Membrane vesicles (2.5 mg protein) prepared from transfected HEK293T cells expressing wild-type MRP1 (WT-MRP1) (A), Tyr1189 mutants Y1189A (B), and Y1189S (C), and Tyr1190 mutants Y1190A (D) and Y1190S (E) were incubated for 3 min at 37 8C with [3 H]E13SO4 (300 nM, 100 nCi) and ATP or AMP.
X
ABCC1 p.Tyr1189Ser 15652236:177:148
status: NEW183 Apigenin-stimulated GSH uptake by MRP1-enriched membrane vesicles was measured at different substrate concentrations (range 10-2500 mM for WT-MRP1 and 50-10,000 mM for Y1189S) in the presence of 30 mM apigenin.
X
ABCC1 p.Tyr1189Ser 15652236:183:168
status: NEW185 For WT-MRP1, the Km and Vmax values for GSH uptake were 162 mM and 8.9 nmol mgÀ1 20 minÀ1 , respectively; for Y1189S, the Km and Vmax values were 1904 mM and 12.4 nmol mgÀ1 20 minÀ1 , respectively.
X
ABCC1 p.Tyr1189Ser 15652236:185:120
status: NEW194 Effect of sulfonylurea drugs on [3 H]E217bG uptake To determine whether the Tyr to Ser mutations affected the ability of sulfonylureas to modulate the vesicular organic anion transport activity of MRP1, E217bG uptake by the Y1189S and Y1190S mutants in the presence of glibenclamide and tolbutamide was examined.
X
ABCC1 p.Tyr1189Ser 15652236:194:224
status: NEW196 As summarized in Table 2, glibenclamide inhibited E217bG uptake by Y1189S and Y1190S by 26-36% at a concentration of 10 mM and by 78-88% at 100 mM.
X
ABCC1 p.Tyr1189Ser 15652236:196:67
status: NEW199 Probenecid (100 mM) inhibited E217bG transport by the Y1189S mutant by approximately 45%, the Y1190S mutant by 20%, and wild-type MRP1 by 61%.
X
ABCC1 p.Tyr1189Ser 15652236:199:28
status: NEW200 These results indicate that Ser substitution of Tyr1189 or Tyr1190 has no substantial effect on the sensitivity of MRP1 to sulfonylureas.
X
ABCC1 p.Tyr1189Ser 15652236:200:28
status: NEW219 Indeed, the 10-fold difference in Km (GSH) observed for the Y1189S mutant compared to the wild-type protein indicates a substantial G. Conseil et al. / Biochemical Pharmacology 69 (2005) 451-461458 Table 2 Effect of glibenclamide and tolbutamide on E217bG uptake by wild-type and Ser-substituted Tyr1189 and Tyr1190 mutant MRP1 proteins Drug Concentration (mM) %Inhibition of E217bG uptakea Wild-type Y1189S Y1190S Glibenclamide 10 54 Æ 7 36 Æ 11 26 Æ 16 Glibenclamide 100 67 Æ 10 78 Æ 10 88 Æ 10 Tolbutamide 100 5 Æ 7 0 Æ 14 0 Æ 7 Probenecid 100 61 Æ 6 45 Æ 9 20 Æ 10 a The values shown are means of triplicate determinations in a single experiment and are representative of results obtained in two independent experiments. Values have been corrected for different MRP1 expression levels according to the immunoblot shown Fig. 3A. decrease in the uptake affinity of the mutant MRP1 for this tripeptide.
X
ABCC1 p.Tyr1189Ser 15652236:219:60
status: NEWX
ABCC1 p.Tyr1189Ser 15652236:219:401
status: NEW150 Kinetic analysis of [3 H]GSH transport To better understand the basis for the markedly reduced levels of GSH uptake by the Tyr mutants, the kinetic parameters of apigenin-stimulated GSH uptake by the Y1189S mutant were determined and compared to those of wild-type MRP1 (Fig. 6).
X
ABCC1 p.Tyr1189Ser 15652236:150:200
status: NEW153 (A) Immunoblot of membrane vesicles (1 mg protein) prepared from HEK293T cells transfected with wild-type (WT-MRP1a, b, c), and mutant (Y1189A, Y1189S, Y1190A, Y1190S) MRP1 cDNAs as in Fig 3A. (B) Membrane vesicles (20 mg protein) were incubated with 5 mM [a-32 P]-8N3-ATP at 4 8C for 5 min in transport buffer containing 5 mM MgCl2. Samples were photo-crosslinked, resolved by SDS-PAGE and exposed to film.
X
ABCC1 p.Tyr1189Ser 15652236:153:144
status: NEW163 Ala/Ser MRP1 mutants (Y1189A, Y1189S, Y1190A, Y1190S).
X
ABCC1 p.Tyr1189Ser 15652236:163:30
status: NEW168 that the Km (GSH) of Y1189S was increased 10-fold compared to that of wild-type MRP1 (1904 420 mM versus 162 29 mM).
X
ABCC1 p.Tyr1189Ser 15652236:168:21
status: NEW171 Ser mutation (Vmax/Km 103 = 54.9 versus 6.5 for wild-type MRP1 and the Y1189S mutant, respectively).
X
ABCC1 p.Tyr1189Ser 15652236:171:73
status: NEW176 Membrane vesicles (2.5 mg protein) prepared from transfected HEK293T cells expressing wild-type MRP1 (WT-MRP1) (A), Tyr1189 mutants Y1189A (B), and Y1189S (C), and Tyr1190 mutants Y1190A (D) and Y1190S (E) were incubated for 3 min at 37 8C with [3 H]E13SO4 (300 nM, 100 nCi) and ATP or AMP.
X
ABCC1 p.Tyr1189Ser 15652236:176:148
status: NEW182 Apigenin-stimulated GSH uptake by MRP1-enriched membrane vesicles was measured at different substrate concentrations (range 10-2500 mM for WT-MRP1 and 50-10,000 mM for Y1189S) in the presence of 30 mM apigenin.
X
ABCC1 p.Tyr1189Ser 15652236:182:168
status: NEW184 For WT-MRP1, the Km and Vmax values for GSH uptake were 162 mM and 8.9 nmol mg1 20 min1 , respectively; for Y1189S, the Km and Vmax values were 1904 mM and 12.4 nmol mg1 20 min1 , respectively.
X
ABCC1 p.Tyr1189Ser 15652236:184:110
status: NEW193 Effect of sulfonylurea drugs on [3 H]E217bG uptake To determine whether the Tyr to Ser mutations affected the ability of sulfonylureas to modulate the vesicular organic anion transport activity of MRP1, E217bG uptake by the Y1189S and Y1190S mutants in the presence of glibenclamide and tolbutamide was examined.
X
ABCC1 p.Tyr1189Ser 15652236:193:224
status: NEW195 As summarized in Table 2, glibenclamide inhibited E217bG uptake by Y1189S and Y1190S by 26-36% at a concentration of 10 mM and by 78-88% at 100 mM.
X
ABCC1 p.Tyr1189Ser 15652236:195:67
status: NEW198 Probenecid (100 mM) inhibited E217bG transport by the Y1189S mutant by approximately 45%, the Y1190S mutant by 20%, and wild-type MRP1 by 61%.
X
ABCC1 p.Tyr1189Ser 15652236:198:54
status: NEW218 Indeed, the 10-fold difference in Km (GSH) observed for the Y1189S mutant compared to the wild-type protein indicates a substantial G. Conseil et al. / Biochemical Pharmacology 69 (2005) 451-461 458 Table 2 Effect of glibenclamide and tolbutamide on E217bG uptake by wild-type and Ser-substituted Tyr1189 and Tyr1190 mutant MRP1 proteins Drug Concentration (mM) %Inhibition of E217bG uptakea Wild-type Y1189S Y1190S Glibenclamide 10 54 7 36 11 26 16 Glibenclamide 100 67 10 78 10 88 10 Tolbutamide 100 5 7 0 14 0 7 Probenecid 100 61 6 45 9 20 10 a The values shown are means of triplicate determinations in a single experiment and are representative of results obtained in two independent experiments. Values have been corrected for different MRP1 expression levels according to the immunoblot shown Fig. 3A. decrease in the uptake affinity of the mutant MRP1 for this tripeptide.
X
ABCC1 p.Tyr1189Ser 15652236:218:60
status: NEWX
ABCC1 p.Tyr1189Ser 15652236:218:402
status: NEW